Hebert JD, Myers SA, Naba A, et al. Proteomic Profiling of the ECM of Xenograft Breast Cancer Metastases in Different Organs Reveals Distinct Metastatic Niches. Cancer Res. 2020;80(7):1475-1485. doi:10.1158/0008-5472.CAN-19-2961
Terai H, Kitajima S, Potter DS, et al. ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2018;78(4):1044-1057. doi:10.1158/0008-5472.CAN-17-1904
Dardaei L, Wang HQ, Singh M, et al. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018;24(4):512-517. doi:10.1038/nm.4497
Meder L, König K, Dietlein F, et al. LIN28B enhanced tumorigenesis in an autochthonous KRAS-driven lung carcinoma mouse model. Oncogene. 2018;37(20):2746-2756. doi:10.1038/s41388-018-0158-7
Gillette MA, Satpathy S, Cao S, et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell. 2020;182(1):200-225.e35. doi:10.1016/j.cell.2020.06.013
Abazeed ME, Adams DJ, Hurov KE, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013;73(20):6289-98. doi:10.1158/0008-5472.CAN-13-1616
Xu H, Lee MS, Tsai PY, et al. Ablation of insulin receptor substrates 1 and 2 suppresses -driven lung tumorigenesis. Proc Natl Acad Sci U S A. 2018;115(16):4228-4233. doi:10.1073/pnas.1718414115
Christofk HR, Heiden MGV, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230-3. doi:10.1038/nature06734
Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018;8(6):714-729. doi:10.1158/2159-8290.CD-17-1256
Wilson FH, Johannessen CM, Piccioni F, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 2015;27(3):397-408. doi:10.1016/j.ccell.2015.02.005